Journals / MN Kardiyoloji / 2019 / Cilt: 26 - Sayı: 3

Comparison Between Admission B-Type Natriuretic Peptide and Neutrophil to Lymphocyte Ratio for the Prediction of Long Term Prognosis in Patients with Acute Decompensated Heart Failure

Akut Dekompanse Kalp Yetersizliği Olan Hastalarda Uzun Dönem Prognozu Öngördürmede B Tipi Natriüretik Peptid ve Nötrofil Lenfosit Oranının Karşılaştırılması

Pages
127–133
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Neutrophil to lymphocyte ratio, a simple marker that can be derived from a routine complete blood count test was significantly and independently related to major adverse cardiac events in patients with acute decompensated heart failure .

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: B-type natriuretic peptide and neutrophil to lymphocyte ratio have been shown to be as an useful biomarker to predict cardiovascular outcomes.
📊
Key Findings & Data:Material and Method: The study consisted of 106 patients admitted to cardiology clinic with the diagnosis of acute decompensated heart failure with reduced left ventricular ejection fraction (left ventricular ejection fraction≤ 35%).
💡
Conclusion & Impact:Conclusions: Neutrophil to lymphocyte ratio, a simple marker that can be derived from a routine complete blood count test was significantly and independently related to major adverse cardiac events in patients with acute decompensated heart failure .
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: B-type natriuretic peptide and neutrophil to lymphocyte ratio have been shown to be as an useful biomarker to predict cardiovascular outcomes. We aimed to compare the admission B-type natriuretic peptide levels and neutrophil to lymphocyte ratio with regard to their prognostic relevance for predicting the long-term prognosis in patients admitted with acute decompensated heart failure. Material and Method: The study consisted of 106 patients admitted to cardiology clinic with the diagnosis of acute decompensated heart failure with reduced left ventricular ejection fraction (left ventricular ejection fraction≤ 35%). All patients were followed-up at 12 months with regard to major adverse cardiac events which was defined as cardiac death, fatal and non- fatal myocardial infarction, and stroke Results: A total of 23 patients (21.7%) had major adverse cardiac events at follow-up period. Neutrophil to lymphocyte ratio was found to be higher in patients with major adverse cardiac events (2.86±1.57 vs 2.04±1.01, p<0.001). Hemoglobin was significantly lower and plasma B-type natriuretic peptide levels were significantly higher in patients with major adverse cardiac events compared to subjects without major adverse cardiac events. The lymphocyte count and neutrophil to lymphocyte ratio were significantly correlated with Btype natriuretic peptide. In multivariate analysis, neutrophil to lymphocyte ratio (odds ratio=1.095, 95% confidence interval=1.007- 1.190; p=0.034) and hemoglobin (odds ratio=0.682, 95% confidence interval=0.508-0.915; p=0.011) were identified as an independent predictor for major adverse cardiac events. Conclusions: Neutrophil to lymphocyte ratio, a simple marker that can be derived from a routine complete blood count test was significantly and independently related to major adverse cardiac events in patients with acute decompensated heart failure .

Özet

Amaç: B-tipi natriüretik peptit ve nötrofil lenfosit oranının kardiyovasküler sonuçları öngördürmede yararlı bir biyobelirteç olduğu gösterilmiştir. Akut dekompanse kalp yetersizliği ile başvuran hastalarda uzun dönem prognozu öngörmede prognostik önemi açısından başvuru B-tipi natriüretik peptit ve nötrofil lenfosit oranlarını karşılaştırmayı amaçladık. Gereç ve Yöntem: Çalışmaya kardiyoloji kliniğine başvuran ve sol ventrikül ejeksiyon fraksiyonu azalmış akut dekompanse kalp yetersizliği tanısı alan 106 hasta (sol ventrikül ejeksiyon fraksiyonu ≤%35) alındı. Tüm hastalar kardiyak ölüm, ölümcül ve ölümcül olmayan miyokard enfarktüsü ve inme olarak tanımlanan istenmeyen majör kardiyak olay açısından 12 ay takip edildi. Bulgular: Takip süresince, toplam 23 hastada (%21,7) majör kardiyak olay gelişti. Nötrofil lenfosit oranı, majör kardiyak olay gelişen hastalarda daha yüksek bulundu (majör kardiyak olay olan hastalarda 2,86 ± 1,57 ve majör kardiyak olay olmayan hastalarda 2,04±1,01, p<0,001). Majör kardiyak olay geçiren hastalarda hemoglobin anlamlı olarak daha düşüktü ve plazma B-tipi natriüretik peptid düzeyleri anlamlı olarak daha yüksek bulundu. Lenfosit sayısı ve nötrofil lenfosit oranı B-tipi natriüretik peptit ile anlamlı şekilde ilişkili idi. Çok değişkenli analizde, nötrofil lenfosit oranı (olasılık oranı=1,095, % 95 Güven aralığı=1,007-1,190; p=0,034) ve hemoglobin (olasılık oranı=0,682, %95 Güven aralığı=0,508-0,915; p=0,011) majör kardiyak olay için bağımsız öngördürücüler olarak tanımlandı. Sonuç: Rutin tam kan sayımı testinden elde edilebilen basit bir belirteç olan nötrofil lenfosit oranı, akut dekompanse kalp yetersizliği hastalarında istenmeyen majör kardiyak olay ile anlamlı ve bağımsız olarak ilişkilidir

🔖

Cite This Article

SELÇUK, H., SELÇUK, M. T., BALCI, K. G., KUNDURACI, N., ÖZBAY, B., TEMİZER, O., YAYLA, Ç., BALCI, M. M. (2019). Comparison Between Admission B-Type Natriuretic Peptide and Neutrophil to Lymphocyte Ratio for the Prediction of Long Term Prognosis in Patients with Acute Decompensated Heart Failure. MN Kardiyoloji, Cilt: 26 - Sayı: 3, 127–133. https://ajindex.com/articles/297228

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.Eur Heart J. 2012;33:1787-47
  2. Liquori ME, Christenson RH, Collinson PO, Defilippi CR. Cardiac biomarkers in heart failure. Clin Biochem. 2014; 47:327-37
  3. Hermansen SE, Kalstad T, How OJ, Myrmel T. Inflammation and reduced endothelial function in the course of severe acute heart failure. Transl Res. 2011;157:117-27
  4. Huang W, Yin W, Jen H, et al. C-Reactive Protein Levels in Chronic Congestive Heart Failure. Acta Cardiol Sin. 2004; 20:7-14
  5. Selcuk H, Dinc L, Selcuk MT, et al. The relation between differential leukocyte count, neutrophil to lymphocyte ratio and the presence and severity of coronary artery disease. Open J Internal Med. 2012;2:163-69
  6. Cooper HA, Exner DV, Waclawiw MA, Domanski MJ. White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD]). Am J Cardiol. 1999;84:252-7
  7. Santaguida PL, Don-Wauchope AC, Ali U, et al. Incremental value of natriuretic peptide measurement in acute decompensated heart failure (ADHF): a systematic review. Heart Fail Rev. 2014;19:507-19
  8. Mann DL, Young JB. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines. Chest. 1994;105:897-904
  9. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-6
  10. Arruda-Olson AM, Reeder GS, Bell MR, Weston SA, Roger VL. Neutrophilia predicts death and heart failure after myocardial infarction: a community-based study. Circ Cardio - vasc Qual Outcomes. 2009;2:656-62
  11. Reichlin T, Socrates T, Egli P, et al. Use of myeloperoxidase for risk stratification in acute heart failure. Clin Chem. 2010;56:944-51
  12. Tousoulis D, Antoniades C, Koumallos N, Stefanadis C. Proinflammatory cytokines in acute coronary syndromes: from bench to bedside. Cytokine Growth Factor Rev. 2006; 17:225-33
  13. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovasc